{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:44:12Z","timestamp":1791636252798,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Studies investigating rates and risk factors for serious safety events (SSEs) during rituximab treatment of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and related disorders are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Rituximab\u2010treated patients with MS, NMOSD, or related disorders at the Rocky Mountain and New York University MS Care Centers were included. The follow\u2010up period was defined as the time from the initial dose of rituximab up to 12\u00a0months of last dose of rituximab or ocrelizumab (in patients who switched). Clinician\u2010reported and laboratory data were retrospectively collected from electronic medical records.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One\u2010thousand patients were included comprising 907 MS, 77 NMOSD, and 16 related disorders. Patients had a mean follow\u2010up of 31.1\u00a0months and a mean cumulative rituximab dose of 4012\u00a0mg. Of the 169 patients who switched to ocrelizumab, the mean ocrelizumab dose was 1141\u00a0mg. Crude incidence rate per 1000 person\u2010years (PY) for lymphopenia was 19.2, neutropenia 5.6, and hypogammaglobulinemia 17.8. Infections resulting in either hospitalization, IV antibiotics, or using antibiotics \u226514\u00a0days occurred at a rate of 38.6\/1000\u00a0PY. Risk factors for infection were duration of therapy, male gender, increased disability, prior exposure to immunosuppression\/chemotherapy, lymphopenia, and hypogammaglobulinemia. Particularly, wheelchair\u2010bound patients had 8.56\u2010fold increased odds of infections. Crude incidence rates of malignant cancer were 3.5, new autoimmune disease 2.3, thromboembolic event 3.1, and mortality of 5.4 per 1000\u00a0PY.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Rates of SSEs in patients with MS, NMOSD, and related disorders were low. Through properly assessing risk:benefit of B\u2010cell depleting therapy in neuroinflammatory disorders and continual monitoring, clinicians may decrease the risk of serious infections.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acn3.51136","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T06:28:55Z","timestamp":1596781735000},"page":"1477-1487","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Serious safety events in rituximab\u2010treated multiple sclerosis and related disorders"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-9012","authenticated-orcid":false,"given":"Brandi L.","family":"Vollmer","sequence":"first","affiliation":[{"name":"Rocky Mountain Multiple Sclerosis Center, Department of Neurology University of Colorado Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya I.","family":"Wallach","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine, Department of Neurology New York University School of Medicine New York City New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Corboy","sequence":"additional","affiliation":[{"name":"Rocky Mountain Multiple Sclerosis Center, Department of Neurology University of Colorado Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Dubovskaya","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine, Department of Neurology New York University School of Medicine New York City New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-9643","authenticated-orcid":false,"given":"Enrique","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Rocky Mountain Multiple Sclerosis Center, Department of Neurology University of Colorado Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-949X","authenticated-orcid":false,"given":"Ilya","family":"Kister","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine, Department of Neurology New York University School of Medicine New York City New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1352458514561911","article-title":"The Charcot lecture|beating MS: a story of B cells, with twists and turns","volume":"21","author":"Hauser SL","year":"2014","journal-title":"Mult Scler J"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-014-0424-x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4011"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7852-y"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-015-9646-5"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003331"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1637"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2013.08.001"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.12.005"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.09.041"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515594042"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9084759"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","unstructured":"Langer\u2010GouldA SmithJ PiehlF LiB FrisellT. Serious infections in two large US and Swedish Rituximab\u2010treated multiple sclerosis cohorts. American Academy of Neurology Annual Conference. Philadelphia PA2019.","DOI":"10.1212\/WNL.92.15_supplement.S26.007"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.1288.1288"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23059"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2013.10.003"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.06.012"},{"key":"e_1_2_7_24_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1975\u20102016) National Cancer Institute DCCPS Surveillance Research Program released April 2019 based on the November 2018 submission."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25701"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335496"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12502"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb06791.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.008"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facn3.51136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.51136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.51136","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.51136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T12:27:08Z","timestamp":1723379228000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.51136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/acn3.51136"],"URL":"https:\/\/doi.org\/10.1002\/acn3.51136","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"assertion":[{"value":"2020-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}